Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials

Two recently completed phase 3 trials (003 and 004) showed fidaxomicin to be noninferior to vancomycin for curing Clostridium difficile infection (CDI) and superior for reducing CDI recurrences. In both studies, adults with active CDI were randomized to receive blinded fidaxomicin 200 mg twice daily...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Crook, Derrick W., Walker, A. Sarah, Kean, Yin, Weiss, Karl, Cornely, Oliver A., Miller, Mark A., Esposito, Roberto, Louie, Thomas J., Stoesser, Nicole E., Young, Bernadette C., Angus, Brian J., Gorbach, Sherwood L., Peto, Timothy E. A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2012
Soggetti:
Supplement Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3388031/
https://ncbi.nlm.nih.gov/pubmed/22752871
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/cis499
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi